Skip to content Skip to footer
Subscribe Now
Viewpoints_Simon Portsmouth
VIEWPOINTS

Simon Portsmouth, VP, Head of Clinical Development, Shionogi Shares Insights from the New Data on an Antibiotic to Treat Bacterial Infections

Shots: Simon spoke about the new data on FETROJA (cefiderocol), an antibiotic for the treatment of serious Gram-negative (highly resistant) bacterial infections He also talked about Shionogi’s agreement with GARDP & CHAI for the manufacturing and commercialization of cefiderocol in different countries The interview summarizes how Shionogi is advancing by developing medicines to treat serious…
November 7, 2022

Read more

Viewpoints_Martin Kilsgård
VIEWPOINTS

Martin Kilsgård, Head of Product at Trialbee, Shares Insights from the Launch of Trialbee Honey™ Analytics at DPHARM 2022

Shots: Martin gave a detailed view of the newly launched Honey Analytics module associated with the Trialbee Honey™ platform He also talked about the how Trialbee Honey platform will help in the screening and recruiting of patients specifically in remote areas The interview gives a profound understanding of how Trialbee is developing real-time monitoring modules…
November 2, 2022

Read more

Viewpoints_Natalie Shiff
VIEWPOINTS

Natalie Shiff, Associate Medical Director, Janssen Rheumatology Shares Insights from the FDA Approval of Stelara to Treat Pediatric Patients with Active Psoriatic Arthritis

Shots: Natalie spoke about the study design and key findings from the P-III study evaluating Stelara for the treatment of pediatric patients with active psoriatic arthritis She also spoke about the patient support program that is executed by Janssen to support patients to get Stelara  The interview gives an understanding of how Janssen is advancing…
October 31, 2022

Read more

Viewpoints_Garret Hampton
VIEWPOINTS

Garret Hampton, President, Clinical Sequencing & Oncology at Thermo Fisher Scientific Shares Insights from the Approval of the First NGS-Based Companion Diagnostic for HER2-Mutant NSCLC

Shots: Garret spoke about the approval of the first NGS-based companion diagnostic to aid in selecting NSCLC patients with HER2  activating mutations for treatment with ENHERTU Garret also talked about the Oncomine Dx Target Test and its availability for different targeted therapies in multiple geographies The interview highlights how Thermo Fisher is working to develop accessible CDx solutions…
October 25, 2022

Read more

Viewpoints_Josh Rubel
VIEWPOINTS

Josh Rubel, CCO at MDClone, Shares Insights on the Partnership with MCI Onehealth to Accelerate Research through Global Clinical Intelligence Offering

Shots: Josh spoke about the collaboration with MCI Onehealth. The collaboration will provide access to high-value data insights as a service for an array of research, clinical, and data science needs Josh also talked about MDClone’s ADAMS platform which has a unique ability to convert datasets and cohorts of interest into synthetic files that are…
October 19, 2022

Read more

Viewpoints_Jonathan Wall
VIEWPOINTS

Jonathan Wall, Co-founder & Interim CSO at Attralus Share Insights from its New Data Presented across its Amyloidosis Portfolio at the 2022 International Symposium on Amyloidosis

Shots: Jonathan spoke about the data presented by Attralus at the XVIII International Symposium on Amyloidosis (ISA) as both oral and poster presentations Jonathan also talked about its lead candidate, AT-01. He discussed the study design of the P-I/II clinical trial evaluating AT-01 The interview highlights Attralus vision to develop innovative medicines to improve the…
October 17, 2022

Read more

Viewpoints_Michael Scheffler
VIEWPOINTS

Michael Scheffler, Vice President, Head of Life Science PCR at QIAGEN Shares Insights on the Addition of New Biopharma Products to its Digital PCR Portfolio

Shots: Michael spoke about the addition of new biopharma products through QIAcuity series of digital PCR (dPCR) instruments to its digital PCR portfolio He also talked about how QIAGEN’s dPCR assays are quicker than systems as it was launched in four different master mixes allowing experiments leading to precise results The interview gives an understanding of…
October 12, 2022

Read more

Viewpoints_Alex Zimmerman_Alexander Lin
VIEWPOINTS

Alex Zimmerman and Alexander Lin Share Insights on the FDA Breakthrough Device Designation Received for Non-Invasive Virtual Biopsy Technology

Shots: Alex Zimmerman talked about virtual biopsy technology using standard MRI scanners. The technology will allow doctors to understand brain imaging via chemical indicators more extensively Alexander Lin spoke about the data on which the BDD was granted by the FDA and the usage of Magnetic Resonance Spectroscopy (MRS) by this software BrainSpec is a…
October 10, 2022

Read more

Viewpoints_Erika Ross
VIEWPOINTS

Erika Ross, Director of Clinical & Applied Research at Abbott Shares Insights on FDA Breakthrough Device Designation to Explore its DBS System to Treat Treatment-Resistant Depression

Shots:  Erika spoke about the FDA Breakthrough Device Designation received by Abbott to investigate its deep brain stimulation (DBS) system to treat treatment-resistant depression (TRD) Erika also talked about how NeuroSphere Virtual Clinic is compatible with the  deep brain stimulation (DBS) system  The interview gives an understanding of Abbott’s vision to bring life-changing technologies in…
October 5, 2022

Read more

Viewpoints_Yoshio Okubo
VIEWPOINTS

Yoshio Okubo, Senior Director, Head of Pandemic Global Product Team for Takeda Shares Insights on the Approval of its Covid-19 Vaccine

Shots: Yoshio spoke about the approval of the Nuvaxovid COVID-19 Vaccine for Primary and Booster Immunization in Japan. Nuvaxovid Intramuscular Injection is the first recombinant protein-based COVID-19 vaccine approved for use in Japan Yoshio also talked about Takeda’s collaboration with Novavax for the development, manufacturing, and commercialization of Nuvaxovid in Japan Further, the interview highlighted…
October 4, 2022

Read more

Load more